Table 3.

Pharmacology of commonly used DOACs and warfarin

	Dabigatran	Rivaroxaban	Apixaban	Warfarin
Mechanism of action	Selective thrombin inhibitor	Selective Xa inhibitor	Selective Xa inhibitor	Vitamin K epoxide reductase inhibitor
Oral bioavailability (%)	6.5	80–100	50	79–100
Half-life (h)	12–17	5–13	8–15	45
Renal elimination (%)	85	66	27	92
Time to maximal inhibition (h)	0.5–2	1–4	1–4	69